Vorinostat

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

2006

www.ebi.ac.uk

First approval year: 2006
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Vorinostat
www.ebi.ac.uk

Molecular weight: 264.32
www.ebi.ac.uk

Structure (SMILES): O=C(CCCCCCC(=O)Nc1ccccc1)NO
www.ebi.ac.uk

zolinza
Zolinza

azacitidine and oral vorinostat
mk 0683
MK-0683
mk0683
MK0683
N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
nsc 701852
nsc 748799
nsc 759852
NSC-701852
NSC-748799
NSC-759852
suberoylanilide hydroxamic acid
Suberoylanilide hydroxamic acid
vorinostat
Vorinostat
VORINOSTAT
vorinostat (MK0683 )
Vorinostat (SAHA)
vorinostat (suberoylanilide hydroxamic acid)
Vorinostat (VOR)
vorinostat [INN]
VORINOSTAT [JAN]
VORINOSTAT [MART.]
VORINOSTAT [MI]

And 14 more, listed on the interactive page.

ATC classification codes

L01XH01

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

149647-78-9

ChEMBL ID: CHEMBL98
www.ebi.ac.uk

InChIKey: WAEXFXRVDQXREF-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

5311

RxNorm IDs (RxCUI)

194337

FDA ingredient codes (UNII)

58IFB293JI

Applicant: MSD SUB MERCK
Approval date: 6 Oct 2006
Application number: NDA021991

Status: application_withdrawn
Status date: 13 Feb 2009
Product number: EMEA/H/C/000947
Authorisation holder: Merck Sharp Dohme Limited
Priority medicines scheme: No
Generic: No
Biosimilar: No
Generic medicines: 0
Biosimilar medicines: 0
Advanced therapy: No
Conditional approval: No
Additional monitoring: No
Accelerated assessment: No
Exceptional circumstances: No

Therapeutic areas

Lymphoma, T-Cell, Cutaneous

European medicines record

www.ema.europa.eu

Patents: 3
Designations: 3
Earliest recorded loss of exclusivity: 18 Mar 2028
First in class: No
Fast track: Yes
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only

Pharmacology name: vorinostat
Type: Synthetic organic
Drug name stem: -stat
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 3
Gene symbol
HDAC3
Protein identifier
O15379
Median affinity
8.3
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 1
Gene symbol
HDAC1
Protein identifier
Q13547
Median affinity
8.89
Affinity units
pKi
Primary target
Yes
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 2
Gene symbol
HDAC2
Protein identifier
Q92769
Median affinity
8.8
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 10
Gene symbol
HDAC10
Protein identifier
Q969S8
Median affinity
7.3
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 11
Gene symbol
HDAC11
Protein identifier
Q96DB2
Median affinity
7.44
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 8
Gene symbol
HDAC8
Protein identifier
Q9BY41
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 6
Gene symbol
HDAC6
Protein identifier
Q9UBN7
Median affinity
8.8
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 9
Gene symbol
HDAC9
Protein identifier
Q9UKV0
Median affinity
7.19
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
histone deacetylase 5
Gene symbol
HDAC5
Protein identifier
Q9UQL6
Median affinity
5.44
Affinity units
pKi
Mechanism
Histone deacetylase 1 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 1
Protein identifier
Q13547
Mechanism
Histone deacetylase 2 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 2
Protein identifier
Q92769
Mechanism
Histone deacetylase 3 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 3
Protein identifier
O15379
Mechanism
Histone deacetylase 6 inhibitor
Action type
Inhibitor
Target
Protein deacetylase HDAC6
Protein identifier
Q9UBN7

Mechanism
Histone deacetylase 1 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 1
Mechanism
Histone deacetylase 2 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 2
Mechanism
Histone deacetylase 3 inhibitor
Action type
Inhibitor
Target
Histone deacetylase 3
Mechanism
Histone deacetylase 6 inhibitor
Action type
Inhibitor
Target
Protein deacetylase HDAC6

Action type
Inhibitor
Gene symbol
HDAC3
Protein identifier
O15379
Organism
Homo sapiens
Target development level
Clinical
Action type
Inhibitor
Gene symbol
HDAC1
Protein identifier
Q13547
Organism
Homo sapiens
Target development level
Clinical
Action type
Inhibitor
Gene symbol
HDAC2
Protein identifier
Q92769
Organism
Homo sapiens
Target development level
Clinical
Action type
Inhibitor
Gene symbol
HDAC6
Protein identifier
Q9UBN7
Organism
Homo sapiens
Target development level
Clinical

Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Highest recorded phase
2
Condition identifier
EFO:0000095
Subject identifier
D015451
Condition
Lymphoma, Follicular
Highest recorded phase
2
Condition identifier
EFO:0000096
Subject identifier
D008224
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000180
Subject identifier
D015658
Condition
Carcinoma, Squamous Cell
Highest recorded phase
1
Condition identifier
EFO:0000181
Subject identifier
D002294
Condition
Hodgkin Disease
Highest recorded phase
2
Condition identifier
EFO:0000183
Subject identifier
D006689
Condition
Lymphoma, B-Cell, Marginal Zone
Highest recorded phase
2
Condition identifier
EFO:0000191
Subject identifier
D018442
Condition
Myelodysplastic Syndromes
Highest recorded phase
2
Condition identifier
EFO:0000198
Subject identifier
D009190
Condition
Neoplasms, Plasma Cell
Highest recorded phase
1
Condition identifier
EFO:0000200
Subject identifier
D054219
Condition
Lymphoma, T-Cell, Peripheral
Highest recorded phase
1
Condition identifier
EFO:0000211
Subject identifier
D016411
Condition
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Highest recorded phase
2
Condition identifier
EFO:0000220
Subject identifier
D054198
Condition
Leukemia, Myeloid, Acute
Highest recorded phase
3
Condition identifier
EFO:0000222
Subject identifier
D015470
Condition
Leukemia, Promyelocytic, Acute
Highest recorded phase
1
Condition identifier
EFO:0000224
Subject identifier
D015473
Condition
Burkitt Lymphoma
Highest recorded phase
1
Condition identifier
EFO:0000309
Subject identifier
D002051
Condition
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Highest recorded phase
1
Condition identifier
EFO:0000339
Subject identifier
D015464
Condition
Carcinoma, Renal Cell
Highest recorded phase
2
Condition identifier
EFO:0000349
Subject identifier
D002292
Condition
Colorectal Neoplasms
Highest recorded phase
2
Condition identifier
EFO:0000365
Subject identifier
D015179
Condition
Crohn Disease
Highest recorded phase
1
Condition identifier
EFO:0000384
Subject identifier
D003424
Condition
Lymphoma, Large B-Cell, Diffuse
Highest recorded phase
1
Condition identifier
EFO:0000403
Subject identifier
D016403
Condition
Thrombocythemia, Essential
Highest recorded phase
2
Condition identifier
EFO:0000479
Subject identifier
D013920
Condition
Adenocarcinoma, Follicular
Highest recorded phase
2
Condition identifier
EFO:0000501
Subject identifier
D018263
Condition
Glioblastoma
Highest recorded phase
2
Condition identifier
EFO:0000519
Subject identifier
D005909
Condition
Leukemia
Highest recorded phase
2
Condition identifier
EFO:0000565
Subject identifier
D007938
Condition
Lymphoma
Highest recorded phase
3
Condition identifier
EFO:0000574
Subject identifier
D008223
Condition
Mesothelioma
Highest recorded phase
3
Condition identifier
EFO:0000588
Subject identifier
D008654
Condition
Neoplasms
Highest recorded phase
4
Condition identifier
EFO:0000616
Subject identifier
D009369

And 71 more, listed on the interactive page.

Condition identifier
EFO_0000096
Highest recorded phase
2
Condition identifier
EFO_0000180
Condition identifier
EFO_0000183
Highest recorded phase
2
Condition identifier
EFO_0000198
Highest recorded phase
2
Condition identifier
EFO_0000211
Condition identifier
EFO_0000222
Highest recorded phase
3
Condition identifier
EFO_0000384
Condition identifier
EFO_0000479
Highest recorded phase
2
Condition identifier
EFO_0000501
Highest recorded phase
2
Condition identifier
EFO_0000519
Highest recorded phase
1
Condition identifier
EFO_0000565
Highest recorded phase
2
Condition identifier
EFO_0000574
Highest recorded phase
3
Condition identifier
EFO_0000588
Highest recorded phase
3
Condition identifier
EFO_0000616
Condition identifier
EFO_0000621
Highest recorded phase
2
Condition identifier
EFO_0000641
Highest recorded phase
2
Condition identifier
EFO_0000681
Highest recorded phase
2
Condition identifier
EFO_0000702
Condition identifier
EFO_0000756
Highest recorded phase
2
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0001378
Highest recorded phase
3
Condition identifier
EFO_0002429
Highest recorded phase
2
Condition identifier
EFO_0002618
Condition identifier
EFO_0002913
Condition identifier
EFO_0003060

And 140 more, listed on the interactive page.

Event
activated partial thromboplastin time prolonged
Reports
17
Reporting signal score
45.3588
Event
acute febrile neutrophilic dermatosis
Reports
6
Reporting signal score
15.112
Event
anaemia
Reports
74
Reporting signal score
68.4043
Event
anorexia
Reports
9
Reporting signal score
13.2887
Event
blood creatinine increased
Reports
19
Reporting signal score
13.3526
Event
decreased appetite
Reports
45
Reporting signal score
36.1278
Event
dehydration
Reports
67
Reporting signal score
88.4422
Event
diarrhoea
Reports
74
Reporting signal score
21.9022
Event
electrocardiogram qt prolonged
Reports
36
Reporting signal score
57.6679
Event
electrolyte imbalance
Reports
9
Reporting signal score
14.0681
Event
embolism
Reports
12
Reporting signal score
25.9419
Event
febrile neutropenia
Reports
104
Reporting signal score
230.271
Event
haematotoxicity
Reports
12
Reporting signal score
22.8181
Event
hyperglycaemia
Reports
24
Reporting signal score
35.5265
Event
hyperuricaemia
Reports
6
Reporting signal score
12.1799
Event
hypocalcaemia
Reports
13
Reporting signal score
16.1405
Event
hypokalaemia
Reports
33
Reporting signal score
45.915
Event
hyponatraemia
Reports
20
Reporting signal score
13.6187
Event
hypophosphataemia
Reports
17
Reporting signal score
41.8787
Event
hypoxia
Reports
14
Reporting signal score
14.0953
Event
infection
Reports
25
Reporting signal score
14.4101
Event
lymphocyte count decreased
Reports
11
Reporting signal score
12.8054
Event
lymphopenia
Reports
36
Reporting signal score
87.1088
Event
mucosal inflammation
Reports
15
Reporting signal score
16.8418
Event
mycosis fungoides
Reports
9
Reporting signal score
32.1662

And 12 more, listed on the interactive page.

NCT00005634
clinicaltrials.gov
NCT00109109
clinicaltrials.gov
NCT00111813
clinicaltrials.gov
NCT00310024
clinicaltrials.gov
NCT00642954
clinicaltrials.gov
NCT00729118
clinicaltrials.gov
NCT00744354
clinicaltrials.gov
NCT00773747
clinicaltrials.gov
NCT00773838
clinicaltrials.gov
NCT00839956
clinicaltrials.gov
NCT00857324
clinicaltrials.gov
NCT00858234
clinicaltrials.gov
NCT01038388
clinicaltrials.gov
NCT01297764
clinicaltrials.gov
NCT01394354
clinicaltrials.gov
NCT01492881
clinicaltrials.gov
NCT01501370
clinicaltrials.gov
NCT01502085
clinicaltrials.gov
NCT01554852
clinicaltrials.gov
NCT01720875
clinicaltrials.gov
NCT02114502
clinicaltrials.gov
NCT00330161
clinicaltrials.gov
NCT01174199
clinicaltrials.gov
NCT06145633
clinicaltrials.gov
NCT00816283
clinicaltrials.gov

And 176 more, listed on the interactive page.

Dose: 400mg
Route: Oral
How often: Once daily

Conditions of use

Take with food

Hydrogen bond acceptors: 3
Hydrogen bond donors: 3
Polar surface area: 78.43
Calculated partition coefficient (ALogP): 2.47
Calculated partition coefficient (XLogP): 1.9
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 8
Heavy atoms: 19
Molecular formula: C14H20N2O3
Monoisotopic mass: 264.14739250
Natural product: Yes

0006-0568

Recorded assays: 15,429
Active assays: 7,109

Confirmatory
Other
Screening
Summary

Antineoplastic Agents
id.nlm.nih.gov
Histone Deacetylase Inhibitors
id.nlm.nih.gov

These details could not be displayed.

Related records

Trials (342)

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

Approved for (4)

Cancer
Neoplasm
Primary cutaneous T-cell non-Hodgkin lymphoma
T-cell non-Hodgkin lymphoma

In development for (94)

Acquired polycythemia vera Phase 2
ACTH-dependent Cushing syndrome Phase 2
Acute leukemia of ambiguous lineage Phase 2
Acute lymphoblastic leukemia Phase 2
Acute myeloid leukemia Phase 3
Acute promyelocytic leukemia Phase 1
Adult glioblastoma Phase 2
Alzheimer disease Phase 1
Anaplastic astrocytoma Phase 2
Anaplastic oligodendroglioma Phase 1
Anus cancer Phase 1
B-cell chronic lymphocytic leukemia Phase 2
Brain cancer Phase 2
Brain disorder Phase 2
Brain neoplasm Phase 2
Breast cancer Phase 2
Breast neoplasm Phase 2
Burkitt lymphoma Phase 1
Childhood acute lymphoblastic leukemia Phase 2
Chronic myeloid leukemia Phase 1

Targets (4)

HDAC1 Histone deacetylase 1 inhibitor
HDAC2 Histone deacetylase 2 inhibitor
HDAC3 Histone deacetylase 3 inhibitor
HDAC6 Histone deacetylase 6 inhibitor

Vorinostat

Development status

Names and chemistry

Brand names (2)

Other names (39)

Identifiers

Regulatory information

United States

European Union

Therapeutic areas

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (13)

Open Targets mechanisms (4)

DrugCentral mechanisms (4)

Investigated indications (96)

Open Targets indications (165)

Reported adverse events (37)

Trial references (201)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Biological measurements

Related records

Trials (342)

Approved for (4)

In development for (94)

Targets (4)